agar was used for aerobes, Wilkins-Chalgren agar was used for anaerobes and Proteose No. 3 agar (GIBCO Laboratories, Madison, Wisconsin) with hemoglobin 1 % and Kellogg supplement 1 % (an enrichment solution containing glucose 40%, glutamine 1 %, thiamine pyrophosphate 0.002% and Fe(NO3)3-9H2O0.085%) was used for N. gonorrhoeae. N. gonorrhoeae was incubated in a 7%CO2 atmosphere. Candida albicans was tested by an analogous 2-fold agar dilution methodusing yeast nitrogen base agar buffered at pH 7 and containing 0.5 % glucose.7) To assess the bioavailability of unphenelfamycin in the presence of hamster caecal contents, MICs and MBCs were determined in Wilkins-Chalgren broth which had been mixed with caecal material. Caecal material (approximately 0.5 g) was suspended by vigorous vortexing into 10 ml broth containing unphenelfamycin at a concentration of 256^g/ml. The mixture was allowed to stand at room temperature for 30 minutes followed by centrifugation at 1,000 xg to pellet solid matter. The supernatant material was then filtered through gauze mesh, a 0.8-/mi nitrocellulose filter and finally sterilized by passage through a 0.2-^m nitrocellulose filter. Broth containing unphenelfamycin but without caecal material was included as a control. MICs for C. difficile ATCC9689 were determined by a 2-fold microdilution method/ MBCswere determined by plating 10 [A aliquots from each well showing no growth and from the well containing one-half the MIC onto drug-free agar followed by 48-hour incubation. Rejection values for determining 99.9% killing were as previously published.8)
Time-kill Studies
The bactericidal activity of unphenelfamycin (MIC 8^g/ml) and vancomycin (MIC 1^g/ml) against C. difficile ATCC9689 over time was determined in Wilkins-Chalgren broth by a method previously described.9) Viability of C. difficile ATCC9689 was determined at 0.5, 1, 2, 4, 6 and 24 hours after exposure to four and eight times the MICof the compounds.
Frequency of Resistance The frequency of spontaneous resistance development by C. difficile ATCC9689 to four and eight times the MICof unphenelfamycin was determined in Wilkins-Chalgren agar by a previously described method.10)
Hamster Model for Pseudomembranous Colitis The hamster colitis test used in this study has been described previously.11>12) Male Golden Syrian hamsters, weighing 80~100 g, were purchased from Harlan Sprague Dawley, Inc., Indianapolis, Indiana. The hamsters were caged in groups of five and were given Purina Rodent Chowand water ad libitum. After a quarantine period of 7 days, the hamsters were exposed to C. difficile ATCC9689 by addition of 106 bacteria per ml in their drinking water. Viable cell counts were performed immediately after the addition of C. difficile to drinking water. Following exposure to C. difficile the hamsters were immediately challenged with lOO mg/kg clindamycin by oral gavage. Beginning 8 hours after clindamycin treatment hamsters received 25 mg/kg/day vancomycin or phenelfamycin A. Both compoundswere administered orally by gavage in a volume of 0.5 ml. Ten animals were used in each treatment group. Twoanimals from each treatment group were sacrificed 1, 4 and 7 days after clindamycin treatment. The caecal contents were removedfrom each of these hamsters and analyzed for C. difficile antigens using a rapid latex slide agglutination test (Marion Laboratories, Kansas City, Missouri). An increase in this antigen has been correlated with disease in humans.13) The remaining four hamsters from each treatment group were monitored for 16 days and the cumulative mortality during this period was recorded. Prior to running this test, enumeration of the caecal micro flora was carried out in hamsters before and after administration of clindamycin to insure that the presence of C. difficile antigens correlated with changes in flora known to be associated with antibiotic-induced pseudomembranous colitis. Caecal contents were weighed, then added to 10 ml prereduced thioglycolate broth on ice. Ten-fold dilutions of this suspension were cultured aerobically on Columbia sheep blood agar and MacConkeyagar and anaerobically on reducible Columbia sheep blood agar with and without kanamycinand on CCFA, a selective mediumcontaining cycloserine, cefoxitin, fructose and egg yolk agar (GIBCO).
Pharmacokinetic Studies in Hamsters JAN. 1989 Male Golden Syrian hamsters, weighing 80~100 g, were administered 25 mg/kg phenelfamycin A orally. At 1, 2, 3 and 6 hours after administration, blood and caecal contents were collected from groups of two hamsters. Samples of serum and caecal contents were assayed for phenelfamycin A by HPLC. The HPLCmethodology is described elsewhere.6)
Results
In Vitro Activity The MICsof phenelfamycin A and efrotomycin for a variety of aerobic organisms are shown in Table 1 . Both compounds have activity against Streptococci. The MICs of phenelfamycin A for N. gonorrhoeae are generally the same as or within one 2-fold dilution of those of erythromycin A ( Table 2 ). Phenelfamycins A through F and unphenelfamycin are more active against Gram-positive anaerobes than against Gram-negative anaerobes (Table 3) ; the phenelfamycins are more active than unphenelfamycin and as active as efrotomycin against Gram-positive anaerobes. MICsof phenelfamycins and unphenelfamycin for C. difficile are shown in Table 4 . Phenelfamycins E and F are one to two 2-fold dilutions more active than phenelfamycin C which is generally one to two 2-fold dilutions more active than phenelfamycins A and B which are generally one to three 2-fold dilutions more active than unphenelfamycin against C. difficile. Phenelfamycins E and F were two to four 2-fold dilutions Table 2 . Activity of phenelfamycin A and erythromycin against Neisseria gonorrhoeae. MICs of phenelfamycin A for nine strains of C. albicans were > 100 /^g/ml.
The MICand MBCof unphenelfamycin in the presence of hamster caecal material for C. difficile ATCC9689 was 64 and 128 /*g/ml, respectively, while the control MIC and MBCwere 4 and 16 A*g/ml, respectively.
Time-kill Studies
Viable cell counts of C. difficile ATCC9689 at the beginning of time-kill studies were approximately 1.0x l06 cfu/ml. Viable cell counts after exposure to four and eight times the MIC of unphenelfamycin remained constant at all sampling times. Viable cell counts after exposure to four and eight times the MIC of vancomycin were reduced 99 % and > 99.9 % at 6 and 24 hours, respectively.
Frequency of Resistance
The frequency of spontaneous resistance by C. difficile ATCC9689 to four and eight times the MIC of unphenelfamycin was 1.0 x 10~8 and <1.0 x 10"8, respectively.
In Vivo Activity After administration of clindamycin all control hamsters died within 5 days. These animals were lethargic and had diarrhea prior to death. Necropsy revealed distended hemorrhagic caeca containing watery fluid. C. difficile antigens were isolated from the caecal contents of all control hamsters dying during the experiment. Previous testing in our laboratory indicated that the caecal micro flora of hamsters dying after clindamycin administration does undergo changes consistent with antibiotic-associated enterocolitis. These changes include a marked decrease in anaerobic Grampositive cocci and anaerobic Gram-negative bacilli along with an increase in anaerobic Gram-positive bacilli with C. difficile present.
Oral administration of 25 mg/kg/day phenelfamycin A for 5 days prolonged the survival of clindamycin challenged hamsters. As indicated in Fig. 1 , phenelfamycin A treated hamsters lived up to 7 days longer than controls. Hamsters receiving an equal dose of vancomycin lived up to 1 1 days longer than controls. The mean-time-to-death in animals receiving vancomycin, phenelfamycin A or no Results of antigen testing indicated that administration of vancomycin or phenelfamycin A delayed the appearance of C. difficile antigens (Table 5) . Hamsters receiving treatment with either agent remained free of C. difficile antigens for at least 7 days after clindamycin challenge. Control animals, however, were positive for antigen as early as 3~4 days after clindamycin treatment. Positive caecal samples were removed from a control animal dying 3 days after clindamycin treatment and from 2 out of 2 hamsters sacrificed 4 days after clindamycin challenge.
Pharmacokinetic Studies
No phenelfamycin Awas detected by HPLCanalysis in the serum or urine of hamsters receiving JAN. 1989 a single oral dose of 25 mg/kg. Levels of phenelfamycin A found in the caecal contents of these animals were 0.4, 0.8, 1.0 and 0.4 //g/g at 1, 2, 3 and 6 hours after administration, respectively.
Discussion
The phenelfamycins, composed of phenelfamycins A, B, C, E, F and unphenelfamycin, are new members of the elfamycin family of antibiotics that are produced by a Streptomyces sp.5) In vitro, the phenelfamycins have activity against Gram-positive anaerobes, including C. difficile. In terms of their structure-activity against C. difficile, the trisaccharides, phenelfamycins E and F, are more potent than the disaccharide, phenelfamycin C, which is more potent than the monosaccharides, phenelfamycins A and B. The MICs of phenelfamycins E and F for C. difficile are generally within one to two 2-fold dilutions of that of efrotomycin.14) Phenelfamycin A also has activity against Streptococci and N. gonorrhoeae. Unphenelfamycin is bacteriostatic for C. difficile ATCC9689; the frequency of spontaneous resistance development by this organism to unphenelfamycin is low.
One of the phenelfamycins, phenelfamycin A, was tested for in vivo activity in a hamster model of C. difficile colitis. This compoundwas selected because of its in vitro potency and because it was available in sufficient quantities at the time of testing. Phenelfamycin Awas also a candidate for in vivo testing because it was not adsorbed after oral administration in hamsters, a characteristic making this compoundmore desirable as a potential therapeutic agent against C. difficile colitis. Whenadministered orally to hamsters phenelfamycin A delayed the development of C. difficile enterocolitis until after phenelfamycin therapy had ceased. Vancomycin, one of the antibiotics currently used
clinically to treat C. difficile colitis, also delayed the onset of fatal colitis in hamsters, but did so for a slightly longer period of time. In the hamster colitis model, vancomycinprevents colonization with C. difficile while it is being administered, but may fail to correct the predisposing conditions within the gut that allow this bacterium to later cause disease.15) Thus, the hamsters remain well until vancomycin therapy is discontinued, after which they develop a fatal enterocolitis because the gastrointestinal flora is not yet refractory to colonization with toxigenic C. difficile. From the present study it appears that the same situation is true in hamsters treated with phenelfamycin A. It should be noted that phenelfamycin A and vancomycin are equally active against C. difficile ATCC9689 in vitro. Other members of the phenelfamycin group, phenelfamycins E and F in particular, are more potent than vancomycinagainst this and other strains of C. difficile in vitro. Thus, other phenelfamycins mayprove to be more effective in treating experimental C. difficile colitis than phenelfamycin A. Phenelfamycins E and F have not yet been tested in the hamster colitis model. Efrotomycin, which is more potent than both vancomycin or phenelfamycin A in vitro against C. difficile,1^has been shown to protect hamsters from C. difficile colitis at a dose of 26 mg/kg.16) Work with unphenelfamycin in the present study suggests that the potency of phenelfamycins may be altered in the presence of caecal contents. This confirms the necessity of testing these compoundsin an animal model for antibiotic associated colitis. The phenelfamycins are a novel family of elfamycins having several structural features not previously encountered in this class. None-the-less their biological properties appear to be very similar to those of other elfamycins.
